Alviol is an early stage MedTech business developing Occoris – inhaler technology that is said to deliver drugs more efficiently to the lungs.
Alviol says that Occoris increases the efficiency of inhaled drug delivery from ~25 percent to 75 per cent and since it is breath-activated, every patient will get the correct dose irrespective of technique or lung capacity. Alviol expects it will set a new standard for respiratory drug delivery over the coming decade.
The company is currently progressing the technology from proof-of-concept into a scalable and robust manufacturing process with Harro Höfliger. Alviol is also working in collaboration with Constantia Flexibles (global providers of pharmaceutical foils) and the University of Hertfordshire.
Alviol is a spin-out from Team Consulting which created Occoris and remains a major shareholder.